Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersRachna T. Shroff, Mitesh J. Borad, Daniel H. Ahn et al.|JAMA Oncology|2019Cited by 472
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerJ.E. Berchuck, Love Goyal, Francesco Facchinetti et al.|Annals of Oncology|2022Cited by 138
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal AdenocarcinomaEugene J. Koay, Jason B. Fleming, Yeon‐Ju Lee et al.|Clinical Cancer Research|2018Cited by 111
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Milind Javle, Ghassan K. Abou‐Alfa et al.|Future Oncology|2020Cited by 91
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinomaLove Goyal, D.C. Bensen, Daniel DiToro et al.|Annals of Oncology|2024Cited by 33